株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性心不全:パイプライン製品の分析

Chronic Heart Failure - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 264093
出版日 ページ情報 英文 156 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
慢性心不全:パイプライン製品の分析 Chronic Heart Failure - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 156 Pages
概要

慢性心不全は、心臓のポンプ機能が低下して、全身に十分な血液・栄養を送ることができなくなる厳しい状況を指します。症状は徐々に進行していきます。一般的に、咳、疲労感、虚弱、失神、食欲不振、夜間の尿意、息切れ、肝臓や腹部の腫れ(肥大)、足・足首のむくみ、体重増加などの症状が見られます。危険因子は、高血圧、冠動脈疾患、心臓発作、糖尿病、アルコール摂取などが挙げられます。

当レポートでは、慢性心不全に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性心不全の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Bayer AG
  • Capricor Therapeutics, Inc.
  • Celyad SA
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Les Laboratoires Servier SAS
  • Mast Therapeutics, Inc.
  • Mesoblast Limited
  • Novartis AG
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Sanofi
  • Stemedica Cell Technologies, Inc.
  • Vichem Chemie Research Ltd.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (sacubitril + valsartan)
  • BAY-1067197
  • beperminogene perplasmid
  • C3BSCQR-1
  • cenderitide
  • CLR-325
  • F-373280
  • finerenone
  • furosemide
  • ivabradine hydrochloride
  • JVS-100
  • MPC-150IM
  • Neucardin
  • omecamtiv mecarbil MR
  • PB-1046
  • rivaroxaban
  • SAR-296968
  • serelaxin
  • クエン酸シルデナフィル
  • 慢性心不全向け小分子
  • 循環器疾患・中枢神経障害・代謝障害・ 呼吸器疾患・感染性疾患・毒物学向け幹細胞療法
  • 循環器疾患向けエリスロポエチン受容体活性合成ペプチド
  • vepoloxamer
  • vericiguat

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8517IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Heart Failure - Pipeline Review, H2 2016, provides an overview of the Chronic Heart Failure (Cardiovascular) pipeline landscape.

Chronic heart failure is a serious condition caused by the heart failing to pump enough blood around the body at the right pressure. The symptoms develop gradually. Common symptoms are cough, fatigue, weakness, faintness, loss of appetite; need to urinate at night, shortness of breath, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. Risk factors that contribute to heart failure are high blood pressure, coronary artery disease, heart attack, diabetes and alcohol use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Heart Failure - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Heart Failure (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Heart Failure (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 9, 11, 2 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Chronic Heart Failure.

Chronic Heart Failure (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Heart Failure (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Chronic Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Heart Failure (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Heart Failure (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Heart Failure Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Heart Failure - Overview
    • Pipeline Products for Chronic Heart Failure - Comparative Analysis
  • Chronic Heart Failure - Therapeutics under Development by Companies
  • Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes
  • Chronic Heart Failure - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Heart Failure - Products under Development by Companies
  • Chronic Heart Failure - Products under Investigation by Universities/Institutes
  • Chronic Heart Failure - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • AnGes MG, Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Capricor Therapeutics, Inc.
    • Celyad SA
    • Juventas Therapeutics, Inc.
    • Laboratoires Pierre Fabre SA
    • Les Laboratoires Servier SAS
    • Mast Therapeutics, Inc.
    • Mesoblast Limited
    • Novartis AG
    • Pfizer Inc.
    • scPharmaceuticals Inc
    • Stemedica Cell Technologies, Inc.
    • Theravance Biopharma, Inc.
    • Vichem Chemie Research Ltd.
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Chronic Heart Failure - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (sacubitril + valsartan) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C3BSCQR-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenderitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLR-325 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dapagliflozin propanediol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-373280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • furosemide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ivabradine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-2286 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPC-150IM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neladenoson bialanate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neucardin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omecamtiv mecarbil MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-38844 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • serelaxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chronic Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-1439 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vepoloxamer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vericiguat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Heart Failure - Dormant Projects
  • Chronic Heart Failure - Discontinued Products
  • Chronic Heart Failure - Product Development Milestones
    • Featured News & Press Releases
      • Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients
      • Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting
      • Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure
      • Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting
      • Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development
      • Aug 28, 2016: CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications
      • Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations
      • Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy
      • Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
      • Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program
      • May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress
      • May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure
      • May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016
      • Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition
      • Apr 26, 2016: Celyad receives certification for C-Cure non-clinical data from the European Medicines Agency
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Heart Failure, H2 2016
  • Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chronic Heart Failure - Pipeline by Amgen Inc., H2 2016
  • Chronic Heart Failure - Pipeline by AnGes MG, Inc., H2 2016
  • Chronic Heart Failure - Pipeline by AstraZeneca Plc, H2 2016
  • Chronic Heart Failure - Pipeline by Bayer AG, H2 2016
  • Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Chronic Heart Failure - Pipeline by Celyad SA, H2 2016
  • Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H2 2016
  • Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
  • Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H2 2016
  • Chronic Heart Failure - Pipeline by Mesoblast Limited, H2 2016
  • Chronic Heart Failure - Pipeline by Novartis AG, H2 2016
  • Chronic Heart Failure - Pipeline by Pfizer Inc., H2 2016
  • Chronic Heart Failure - Pipeline by scPharmaceuticals Inc, H2 2016
  • Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
  • Chronic Heart Failure - Pipeline by Theravance Biopharma, Inc., H2 2016
  • Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H2 2016
  • Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Heart Failure - Dormant Projects, H2 2016
  • Chronic Heart Failure - Dormant Projects (Contd..1), H2 2016
  • Chronic Heart Failure - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chronic Heart Failure, H2 2016
  • Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top